Table 1 Sociodemographic data of patients.
ATB | TBI | HD | p value | |
|---|---|---|---|---|
N = 37 | N = 23 | N = 24 | ||
Patient demographics | ||||
Age (years) | 28 (22–43) | 35 (24.5–44.5) | 29.5 (23.25–36.25) | 0.22 |
Sex (male) | 59.5% (22/37) | 34.8% (8/23) | 20.8% (5/24) | 0.015 |
BMI at inclusion | 17.27 (16.16–18.48) | NA | NA | |
Risk factors and comorbidities | ||||
Smoking | 40.5% (15/37) | NA | NA | |
Alcohol abuse | 40.5% (15/37) | NA | NA | |
Jail detention history | 2.7% (1/37) | NA | NA | |
Chronic HCV infection | 2.7% (1/37) | NA | NA | |
History of TB | ||||
Previous TB | 16.2% (6/37) | NA | NA | |
Previous TB treatment outcome | ||||
Cured and completed | 50% (3/6) | NA | NA | |
Treatment failure | 16.7% (1/6) | NA | NA | |
Outcome not evaluated or unknown | 33.3% (2/6) | NA | NA | |
TB characteristics at inclusion | ||||
Drug-susceptible Mtb | 100% (37/37) | NA | NA | |
Pulmonary TB | 100% (37/37) | NA | NA | |
Sputum smear microscopy at inclusion | ||||
High grade (2+ or 3+) | 40.5% (15/37) | NA | NA | |
Low grade (1+ or scanty) | 27% (10/37) | NA | NA | |
Negative | 32.4% (12/37) | NA | NA | |
Treatment regimen | ||||
2HRZE/2HR | 97.3% (36/37) | NA | NA | |
Slow converters | 32.4% (12/37) | NA | NA | |
Fast converters | 67.6% (25/37) | NA | NA | |
WBC absolute count at inclusion (/mm3) | 8870 (6350–11,360) | 7340 (5875–9230) | 6760 (5920–7132.5) | 0.009 |
Lymphocyte at inclusion (% of WBC) | 17.8 (13–23.9) | 35.2 (30.1–41.4) | 43.1 (38.25–52.67) | < 0.001 |
Monocytes at inclusion (% of WBC) | 9.8 (7–11.5) | 7.2 (6.6–7.75) | 7.65 (6.8–9.47) | 0.001 |
Hemoglobin at inclusion (g/dL) | 11.9 (11–13.1) | 14.4 (13.6–15.35) | 14.35 (13–15.1) | < 0.001 |
Neutrophils at inclusion (% of WBC) | 70.1 (62.7–77.5) | 52 (45.7–58.56) | 44.6 (33.57–48.82) | < 0.001 |
Eosinophil at inclusion (% of WBC) | 1 (0.5–1.9) | 2.6 (1.91–4.99) | 2.71 (2.18–4.28) | < 0.001 |
Basophils at inclusion (% of WBC) | 0.4 (0.1–0.6) | 0.6 (0.5–0.85) | 0.75 (0.5–0.89) | < 0.001 |
BCG vaccination | 91.9% (34/37) | NA | NA | |
Positive QuantiFERON-TB gold plus at baseline | 67.6% (25/37) | 100% (23/23) | 0% (0/24) | |
